Personalis (NASDAQ:PSNL) Sets New 1-Year High – What’s Next?

Personalis, Inc. (NASDAQ:PSNL)’s share price reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $14.18 and last traded at $13.90, with a volume of 461910 shares trading hands. The stock had previously closed at $13.40.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Morgan Stanley lowered their price target on shares of Personalis from $10.00 to $9.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. BTIG Research cut their price objective on shares of Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Monday, May 11th. Wall Street Zen cut shares of Personalis from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a report on Tuesday, April 21st. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.00.

Personalis Price Performance

The stock has a market cap of $1.43 billion, a P/E ratio of -13.35 and a beta of 2.24. The company’s 50 day simple moving average is $8.99 and its 200 day simple moving average is $8.40.

Personalis (NASDAQ:PSNL) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%.The firm had revenue of $15.47 million for the quarter, compared to the consensus estimate of $14.48 million. On average, equities research analysts predict that Personalis, Inc. will post -1.06 earnings per share for the current year.

Insider Activity

In other news, CFO Aaron Tachibana sold 4,982 shares of the firm’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $14.00, for a total transaction of $69,748.00. Following the sale, the chief financial officer owned 198,833 shares of the company’s stock, valued at $2,783,662. This trade represents a 2.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher M. Hall sold 100,000 shares of Personalis stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $13.15, for a total value of $1,315,000.00. Following the transaction, the chief executive officer owned 235,986 shares in the company, valued at $3,103,215.90. This trade represents a 29.76% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 335,032 shares of company stock valued at $4,091,929 over the last 90 days. Corporate insiders own 4.20% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. Bank of America Corp DE boosted its holdings in shares of Personalis by 85.4% in the first quarter. Bank of America Corp DE now owns 111,306 shares of the company’s stock valued at $709,000 after buying an additional 51,273 shares during the period. Janus Henderson Group PLC acquired a new position in Personalis in the 1st quarter worth $192,000. ADAR1 Capital Management LLC bought a new position in Personalis during the 1st quarter worth about $159,000. Sei Investments Co. increased its holdings in Personalis by 148.3% during the 1st quarter. Sei Investments Co. now owns 139,046 shares of the company’s stock worth $886,000 after purchasing an additional 83,040 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in shares of Personalis by 8.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,066,248 shares of the company’s stock valued at $6,791,000 after purchasing an additional 83,074 shares during the period. Institutional investors own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.